VolitionRx posts corporate deck outlining licensing-led strategy for Nu.Q diagnostics in cancer, sepsis, veterinary testing
Reuters2026/08/14 12:49- Volition investor deck outlined an asset-light strategy focused on licensing Nu.Q diagnostics IP in cancer and sepsis.
- Commercial update flagged $23 million in licensing to date, revenue of $1.4 million for H1 2026.
- Company highlighted a potential $5 million contractual milestone tied to a submitted feline paper, contingent on publication.
- Pipeline priorities included human licensing discussions with more than a dozen diagnostics and liquid biopsy groups, targeting multiple deals in 2026.
- Sepsis program update cited DETECSEPS as on track for first patient in Q3 2026, with reimbursement submission in preparation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pi Network’s PI Defends a Critical Support, Bitcoin (BTC) Reclaims $78K: Weekend Watch
Pons: $20.93 million has been paid to token creators over the past 47 days
XRP’s Crazy August Is Almost Over – September Could Be Even Bigger
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Crypto prices
More
